MitoCareX Bio Reports Successful Results in Vitro: MITOLINE™-Powered Small Molecules Show Anti-Inflammatory Potential for Metabolic Syndrome-Related Diseases

Rhea-AI Summary

N2OFF (NASDAQ: NITO) subsidiary MitoCareX Bio reported Feb 12, 2026 in‑vitro data showing MITOLINE™‑powered small molecules reduced pro‑inflammatory markers in human immune cells. The results support further in vivo validation and lead optimization for metabolic syndrome‑related inflammatory indications and expansion of MITOLINE™ discovery programs.

Market Reaction

-12.31% $0.85

15m delay 11 alerts

-12.31% Since News

$0.85 Last Price

$0.83 $1.01 Day Range

-$332K Valuation Impact

$2M Market Cap

0.6x Rel. Volume

Following this news, NITO has declined 12.31%, reflecting a significant negative market reaction. Our momentum scanner has triggered 11 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $0.85. This price movement has removed approximately $332K from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Anti-inflammatory drugs market 2024: $122 billion Anti-inflammatory drugs market 2034: $275 billion Anti-inflammatory CAGR: 8.4% +5 more

8 metrics

Anti-inflammatory drugs market 2024 $122 billion Global anti-inflammatory drugs market size in 2024

Anti-inflammatory drugs market 2034 $275 billion Forecast global anti-inflammatory drugs market by 2034

Anti-inflammatory CAGR 8.4% Projected 2024–2034 CAGR for anti-inflammatory drugs

Immunomodulators 2025 $188 billion Projected 2025 market for small-molecule immunomodulators

Immunomodulators 2035 $350 billion Forecast 2035 market for small-molecule immunomodulators

Immunomodulators CAGR 6.5% Projected 2025–2035 CAGR for small-molecule immunomodulators

Metabolic disorder market 2024 $77 billion Estimated 2024 market for metabolic disorder therapeutics

Metabolic disorder market 2030 $120 billion Forecast 2030 market for metabolic disorder therapeutics

Market Reality Check

Price: $0.9740 Vol: Volume 34,662 vs 20-day a...

low vol

$0.9740 Last Close

Volume Volume 34,662 vs 20-day average 2,488,079 indicates very light trading interest ahead of this news. low

Technical Shares trade below the 200-day MA at 5.99, reflecting a prolonged downtrend before this update.

Peers on Argus

NITO was down 4.51% while peers were mixed: SEED -3.48%, ENFY -33.38%, SANW 0%, ...

NITO was down 4.51% while peers were mixed: SEED -3.48%, ENFY -33.38%, SANW 0%, BIOX +4.84%, AVD +2.98%, suggesting stock-specific dynamics rather than a unified agricultural inputs move.

Historical Context

5 past events · Latest: Feb 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 02	Spaceflight study highlight	Positive	-7.1%	Showcased peer‑reviewed research on SLC25 mitochondrial carriers in spaceflight stress conditions.
Jan 22	In vitro results	Positive	+9.7%	Reported MITOLINE™‑derived small molecules reducing pro‑inflammatory markers in immune cells.
Jan 15	Mitochondrial research focus	Positive	+5.4%	Highlighted microgravity study on 53 SLC25A genes supporting MitoCareX computational platform.
Jan 05	Solar project payment	Positive	+0.0%	Advanced $340,000 to improve economics and potential profits in flagship solar initiative.
Dec 29	Renewables de-risking	Positive	-19.4%	Reported de‑risking milestones and about $1.69M value unlock in Germany and Italy.

Pattern Detected

Recent MitoCareX and renewable energy announcements were generally positive, yet price reactions have been mixed with several notable selloffs on ostensibly constructive updates.

Recent Company History

Over the last few months, N2OFF has alternated between biotech and renewable energy milestones. MitoCareX-related news on mitochondrial carriers and the MITOLINE™ platform (e.g., in vitro results and spaceflight-stress research) previously saw both gains and losses, including moves of +9.7%, +5.42%, and -7.14%. Separately, European solar portfolio actions and value unlocks around $1.69–$1.7 million sometimes coincided with sharp declines, such as a -19.37% reaction, underscoring inconsistent market reception to strategic progress.

Market Pulse Summary

The stock is dropping -12.3% following this news. A negative reaction despite positive in vitro find...

Analysis

The stock is dropping -12.3% following this news. A negative reaction despite positive in vitro findings fits a pattern where NITO has sometimes sold off on constructive updates, such as a -19.37% move after European renewable milestones and a -7.14% move following earlier MitoCareX research news. The stock already traded well below its 5.99 200-day MA and far beneath its 52-week high of 40.6, so some holders may have focused on broader balance sheet and strategic complexities rather than early-stage biotech potential.

Key Terms

in vitro, metabolic syndrome, immunomodulators, oncology, +2 more

6 terms

in vitro medical

"has shown preliminary in vitro data demonstrating inhibition of pro‑inflammatory"

In vitro describes laboratory tests performed on cells, tissues, or biological molecules outside a living body—literally “in glass,” such as in test tubes or dishes. For investors, in vitro results are an early sign that a drug or technology has a desired effect under controlled conditions, but they don’t guarantee it will work or be safe in animals or people; think of them as a prototype tested on a bench rather than in real-world use.

metabolic syndrome medical

"across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome"

A cluster of common health problems—usually high blood pressure, high blood sugar, excess belly fat, and abnormal blood fats—that often occur together and raise the risk of heart disease, stroke and diabetes. Think of it like a car dashboard with several warning lights on at once: because the issues reinforce each other, they lead to bigger long-term healthcare needs and spending. Investors care because it drives demand for drugs, devices, diagnostics, chronic-care services and workplace health programs, shaping market size and regulatory attention.

immunomodulators medical

"small‑molecule immunomodulators alone are projected to expand from around $188 billion"

Drugs or therapies that change how the immune system works, either by boosting, calming, or redirecting its activity; think of them as a thermostat or dimmer switch for immune response. They matter to investors because they are central to treatments for autoimmune diseases, infections and cancer, and regulatory approvals, clinical trial results or manufacturing advances can significantly affect a biotech company’s revenue prospects and stock value.

oncology medical

"engage mitochondrial carriers implicated in oncology, autoimmune, and metabolic‑inflammatory diseases"

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

autoimmune medical

"engage mitochondrial carriers implicated in oncology, autoimmune, and metabolic‑inflammatory diseases"

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

virtual screening technical

"binding sites for its virtual screening campaigns"

Virtual screening is a computer-driven process that tests large libraries of chemical or biological compounds against a disease target to predict which ones are most likely to work. Like using a search engine to shortlist candidates from millions of options, it speeds discovery, cuts early costs, and helps investors gauge how efficiently a company can find promising drug leads before expensive lab tests and trials.

AI-generated analysis. Not financial advice.

MITOLINE^™ Algorithm Powers Development of First-in-Class Small Molecules Targeting a Mitochondrial Carrier for Inflammatory Metabolic Diseases – A Market Projected to Exceed $120 billion by 2030

Neve Yarak, Israel, Feb. 12, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced that MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary, has shown preliminary in vitro data demonstrating inhibition of pro‑inflammatory responses in human immune cells using its proprietary discovery platform.

Using MITOLINE^™‑derived models, MitoCareX has assembled a focused library of small‑molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing MitoCareX Bio with an initial line of evidence that mitochondrial carrier modulation can deliver anti‑inflammatory benefit in human‑relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.

Inflammatory and inflammatory metabolic diseases represent one of the fastest‑growing therapeutic areas in global pharma, with anti‑inflammatory drugs expected to grow from approximately $122 billion in 2024 to nearly $275 billion by 2034 (CAGR ~8.4%). Within this landscape, small‑molecule immunomodulators alone are projected to expand from around $188 billion in 2025 to more than $350 billion by 2035 (CAGR ~6.5%), underscoring strong and sustained demand for oral, targeted anti‑inflammatory therapies. Metabolic disorder therapeutics, which include key inflammatory metabolic diseases such as diabetes and related syndromes, are estimated around $77 billion in 2024 and forecast to surpass $120 billion by 2030.

MitoCareX’s cutting‑edge MITOLINE^™ algorithm overcomes a critical bottleneck in mitochondrial drug discovery: the lack of solved 3D structures for most human mitochondrial carriers. MITOLINE^™ applies advanced sequence based analyses to enable reliable 3D comparative models of mitochondrial carrier proteins, allowing MitoCareX to characterize substrate translocation binding sites for its virtual screening campaigns. This platform supports rapid identification of novel small‑molecule scaffolds that engage mitochondrial carriers implicated in oncology, autoimmune, and metabolic‑inflammatory diseases.

MitoCareX Bio plans to advance its most promising mitochondrial‑targeted anti‑inflammatory candidates toward pre-clinical studies, while continuing to broaden the MITOLINE^™‑powered discovery engine across additional mitochondrial carrier targets.

About N2OFF Inc:

N2OFF owns 100% of MitoCareX Bio Ltd, a drug discovery company engaged in targeting cancer therapeutics and other diseases through the mitochondrial SLC25 protein family. Additionally, N2OFF adopted an investment strategy focused on European renewable energy assets utilizing a RTB (Ready to Build) business model. The Company is currently the lead investor in four solar projects across three European Union countries, all introduced by Solterra Renewable Energy Ltd., a wholly owned subsidiary of Solterra Energy Ltd.

N2OFF also controls approximately 98% of Save Foods Ltd., an Israeli company focused on post-harvest treatment technologies designed to reduce pathogen contamination in fruits and vegetables.

For more information, please visit www.n2off.com.

Forward-looking Statements:

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the expected growth of global anti-inflammatory drugs market, the small molecule immunomodulators market and the global metabolic disorder therapeutics market and how MitoCareX Bio plans to advance its most promising mitochondrial‑targeted anti‑inflammatory candidates toward pre-clinical studies, while continuing to broaden the MITOLINE™‑powered discovery engine across additional mitochondrial carrier targets. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause N2OFF’s and its subsidiaries’ actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of Nasdaq Capital Market; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the “Risk Factors” section of N2OFF’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 31, 2025 and other public reports filed with the SEC. Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. We are not responsible for the contents of third-party websites.

Investor Relations Contact:
Michal Efraty
michal@efraty.com

FAQ

What did NITO announce on February 12, 2026 about MITOLINE™ and MitoCareX Bio?

They reported in‑vitro evidence that MITOLINE™‑derived small molecules reduced key inflammatory markers in human immune cells. According to the company, these results justify advancing candidates to in vivo validation and lead optimization for metabolic inflammatory disease indications.

How could MitoCareX Bio’s MITOLINE™ platform affect NITO (NITO) drug discovery timelines?

MITOLINE™ aims to enable rapid identification of mitochondrial carrier small‑molecule scaffolds for inflammatory diseases. According to the company, the platform bypasses missing 3D structures and accelerates virtual screening and candidate selection toward preclinical studies.

What disease areas is N2OFF targeting with MitoCareX Bio’s MITOLINE™ work (NITO)?

The company targets inflammatory metabolic diseases related to metabolic syndrome, plus oncology and autoimmune indications. According to the company, MITOLINE™ supports discovery across multiple mitochondrial carrier targets implicated in these therapeutic areas.

Do the February 12, 2026 results constitute clinical proof of efficacy for NITO’s programs?

No; the findings are preliminary in‑vitro reductions of inflammatory markers in human immune cells, not clinical proof. According to the company, in vivo validation and further optimization are next steps before clinical evaluation.

What commercial market opportunity did N2OFF cite for inflammatory metabolic therapeutics related to NITO’s announcement?

The company cited markets of roughly $77 billion for metabolic disorder therapeutics in 2024, projected to exceed $120 billion by 2030. According to the company, broader anti‑inflammatory drug markets are also forecast to grow substantially through 2034–2035.

What are N2OFF’s next development steps for MitoCareX Bio’s mitochondrial‑targeted candidates (NITO)?

N2OFF plans in vivo validation and lead optimization of the most promising mitochondrial carrier candidates. According to the company, the MITOLINE™ engine will also be expanded to additional mitochondrial carrier targets to broaden the discovery pipeline.